Solutions Tailored for Your Needs

We have breakthrough solutions and know-how
for your exosome research and utilization

ExosomePlus was founded in 2018 to drive an extracellular vesicle (EV) revolution, bringing the best EV isolation and
characterization platform in the field of regenerative therapy  to bear on research wide
challenges faced by pharmaceutics industry.

Moving discovery from the lab to the real world, ExosomePlus are forming strategic partnerships to help companies integrate high purity exosomes into targeting for greater efficacy, versatility, and results. Our decade of directed exosome and its application R&D before establishment have resulted in more than 10 patents and applications. With a majority of our professional staff and management, advisory board members having doctoral or other higher degrees, our employees bring extensive experience in our target markets. ExosomePlus draws on these human resources to serve the needs of industry leaders in  medical science with our core technology capabilities.

ExosomePlus is proud to be backed by the following industry leading venture capital firms

Advisory Board

Chung-Soo Kim, MD

  • Professor, Urology, Seoul A-San Medical Center
  • Head, A-San Life Science Research Center
  • Visiting professor, Duke University
  • MD, Seoul National University

Yong-Goo Kim, MD / PhD

  • Specialty in transfusion medicine and Molecular genetics
  • Chief, Division of Laboratory Medicine
  • MD, PhD, Catholic University

Ji-Yeol Lee, MD

  • Head, Cancer Research Institute, St. Mary’s Hospital
  • Professor and Head, Division of Prostate, Catholic Medical School
  • President, Asia Pacific Society of Urology

Y. Gianchandani, PhD

  • 35 years of experience of research and business development in Nano/MEMS area
  • Professor, EECS, Univ. of Michigan
  • Director, Engineering Research Center, WIMS
  • Fellow, IEEE

Se-Joong Kim, MD

  • Reviewer, Journal of Korean Medicine and Science, Kidney Research and Clinical practice, Electrolytes and Blood pressure